Paediatric Subanalysis of TSUBASA, Assessing Physical Activity, Bleeding, Quality of Life and Safety in People with Haemophilia A Receiving Emicizumab [0.03%]
佩乐能TSUBASA儿科亚组分析：在甲型血友病合并抑制物患者中评估emicizumab治疗对身体活动、出血及生活质量的影响和安全性
Keiji Nogami,Kagehiro Amano,Akihiro Sawada et al.
Keiji Nogami et al.
Introduction: Limited data are available on the relationship between bleeding outcomes and physical activity, and the quality of daily life (QoL), in children with haemophilia A (HA) receiving emicizumab prophylaxis. ...
Differences and Compatibility between Human and Porcine Fibrinolytic Components toward Plasmin Generation and Fibrin Degradation [0.03%]
人和猪溶栓成分的差异及在生成尿激酶原和溶解纤维蛋白方面的兼容性
Paul Y Kim,Chengliang Wu,Hena Noorzada et al.
Paul Y Kim et al.
Background: Fibrinolysis is the process of blood clot breakdown by the enzyme plasmin. Despite increased usage of large animals such as pigs to study fibrinolysis in human disease models, a comprehensive study comparing t...
Anticoagulant Therapy in Neonatal Acute Infectious Peritonitis Based on the TAT, PIC, t-PAIC, and sTM: A New Case Series [0.03%]
基于TAT、PIC、t-PAIC和sTM的新生儿急性感染性腹膜炎抗凝治疗：新的病例系列
Wenya Wang,Yue Gao,Yan Qiao et al.
Wenya Wang et al.
Neonatal acute peritonitis is a leading cause of morbidity and mortality and poses challenges that demand prompt diagnosis and treatment, particularly in infants with disseminated intravascular coagulation. Here, we report a case series of ...
Bleeding Risk of Central Venous Catheterization in Adults: A Systematic Review and Meta-analysis [0.03%]
成人中心静脉置管出血风险的系统评价和 meta 分析
Nicola Mumoli,Lucia Colavolpe,Piero Tarantini et al.
Nicola Mumoli et al.
Background: Central venous catheter (CVC) insertion is a cornerstone procedure in hospitalized and critically ill adults. However, many patients requiring CVCs have coagulopathy, thrombocytopenia, liver disease, or hemato...
Identification of Prothrombin Belgrade Variant in a Mexican-American Family with Recurrent Deep Vein Thrombosis [0.03%]
在具有复发性深静脉血栓形成病史的墨西哥美国人家庭中鉴定出贝尔格莱德型凝血酶原变异型
Émile Moura Coelho da Silva,Natalie Montanez,Miguel Escobar
Émile Moura Coelho da Silva
A rare prothrombin variant (c.1787G > A, p.Arg596Gln), also known as the prothrombin Belgrade variant, has been associated with an increased predisposition to thrombosis through resistance to antithrombin. This variant has been previously r...
Edoxaban Overdose in a Child: Unexpected Observation of Clot Lysis [0.03%]
儿童艾-do-xa-班过量事件中意外发现血栓溶解现象
Mouna Sassi,Emna Sfar,Linda Khefacha et al.
Mouna Sassi et al.
Performance Verification of High Sensitivity Analyzer for TAT, PIC, TM, and t-PAIC [0.03%]
高灵敏度TAT、PIC、TM和t-PAIC检测试剂盒的性能验证研究
Yanhong Liu,Bo Guo,Guanghui Chen et al.
Yanhong Liu et al.
Background: Thrombin-antithrombin complex (TAT), a2-plasmininhibitor-plasmin complex (PIC), thrombomodulin (TM), tissue plasminogen activator-plasminogen activator inhibitor complex (t-PAIC) has been increasingly applied ...
Corrigendum: National Early Warning Score for Predicting Clinical Outcome of Acute Pulmonary Embolism in Intermediate-High Risk Patients [0.03%]
急性肺栓塞患者Intermediate-high风险患者急性肺栓塞临床转归的早期预警评分(corrigendum)
Audrey J C Overgaauw,Esther J Nossent,Lilian J Meijboom et al.
Audrey J C Overgaauw et al.
[This corrects the article DOI: 10.1055/a-2719-9061.]. The Author(s). This is an open access article published by Thieme under the terms of the Creative ...
Trends and Predictors of Vena Cava Filter Use (2004-2023): A Swiss Nationwide Epidemiological Study [0.03%]
2004年至2023年期间肺静脉滤器使用趋势及预测因素的全国流行病学研究
Simon Wolf,Pilar Müller,Silvia Cardi et al.
Simon Wolf et al.
Background: Recent data on inferior vena cava filter (IVCF) placement mainly originate from the United States, with limited evidence from Europe. Methods:...
Pharmacokinetic Evidence Supporting Subcutaneous Use of Protein C Concentrate in Patients with Protein C Deficiency [0.03%]
蛋白C缺乏症患者的蛋白C浓缩剂皮下给药的药代动力学证据支持
Zhaoyang Li,Inmaculada C Sorribes,Jennifer Schneider et al.
Zhaoyang Li et al.
Background: Protein C concentrate (Ceprotin®; Baxalta US Inc., a Takeda company, Cambridge, MA; Takeda Manufacturing Austria AG, Vienna, Austria) is approved for intravenous (IV) use in severe congenital protein C defici...